Home › Research › Treatments
Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial
Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D.. Journal of neurology, neurosurgery, and psychiatry, 2001-11-01
Topic: Drug trials: efficacy and safety
Plain-language summary
Objective To assess the efficacy and safety of galantamine in Alzheimer's disease at 3 months using flexible dose escalation. Methods A randomised, double blind, placebo controlled trial in 43 centres in the United States, Canada, Great Britain, South Africa, Australia, and New Zealand. Patients with probable Alzheimer's disease (n=386; 171 women) with a score of 11-24 on the mini mental state examination, and a score> or =12 on the cognitive subscale of the Alzheimer's disease assessment scale (ADAS-cog) were randomised to placebo, or galantamine escalated over 4 weeks to a maintenance dose of 24 or 32 mg/day. The primary outcome measures were the change in ADAS-cog score and the clinician's interview based impression of change plus caregiver input (CIBIC-plus) score. Activities of daily living (ADL) and behavioural symptoms were secondary outcomes. To compare the effects of highest levels of dosing, an observed cases (OC) analysis was undertaken, with classic intention to treat (ITT) and ITT with last observation carried forward (LOCF) as confirmatory analyses. Results At 3 months, galantamine (24-32 mg/day) produced a significantly better outcome on cognitive function than placebo (treatment difference=1.9 points on ADAS-cog, p=0.002) and a significantly better global response than placebo, as measured by CIBIC-plus (deterioration in 21% of patients on galantamine v 37% on placebo; p<0.001). Galantamine produced significant benefits on basic and instrumental ADL. Behavioural symptoms did not change significantly from baseline levels in either group. Adverse events (primarily gastrointestinal) were of mild to moderate intensity. There were no important differences between the OC, ITT, and ITT/LOCF analyses. Most patients (82%) who were maintained on the higher dose of galantamine completed the study. Conclusions Patients on galantamine, compared with those on placebo, experienced benefits in cognitive function and instrumental and basic activities of daily living. Flexible dose escalation of galantamine was well tolerated.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rockwood, K., Mintzer, J., Truyen, L., Wessel, T., & Wilkinson, D. (2001). Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. Journal of neurology, neurosurgery, and psychiatry. https://doi.org/10.1136/jnnp.71.5.589
Vancouver
Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. Journal of neurology, neurosurgery, and psychiatry. 2001. doi:10.1136/jnnp.71.5.589. PMID: 11606667.
BibTeX
@article{rockwood2001-11606667,
author = {Rockwood, K. and Mintzer, J. and Truyen, L. and Wessel, T. and Wilkinson, D.},
title = {{Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial}},
journal = {Journal of neurology, neurosurgery, and psychiatry},
year = {2001},
doi = {10.1136/jnnp.71.5.589},
pmid = {11606667},
url = {https://doi.org/10.1136/jnnp.71.5.589}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results At 3 months, galantamine (24-32 mg/day) produced a significantly better outcome on cognitive function than placebo (treatment difference=1.9 points on ADAS-cog, p=0.002) and a significantly better global response than placebo, as measured by CIBIC-plus (deterioration in 21% of patients on galantamine v 37% on placebo; p<0.001).
- Galantamine produced significant benefits on basic and instrumental ADL.
- Behavioural symptoms did not change significantly from baseline levels in either group.
- Conclusions Patients on galantamine, compared with those on placebo, experienced benefits in cognitive function and instrumental and basic activities of daily living.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants386
- Evidence strengthHigh
How this study scored 56/100
Published in a peer-reviewed journal. Scored zero for study design and effect reported because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record and institution's track record, so those were left out: it earned 34 of the 61 points we could judge it on, which is 56 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of neurology, neurosurgery, and psychiatry) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2001 — older than 20 years, still counted |
| Sample size | 2 / 4 | 386 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 11606667) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 34 / 61 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 34 of the 61 points we could judge it on is 56 out of 100. |
| Total | 56 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “cholinesterase”
272 studies in the library carry the topic tag “cholinesterase”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 272 tagged studies.